Financial Data and Key Metrics Changes - The company recognized CHF0.4 million of income in Q3 2022, a decrease from CHF0.8 million in Q3 2021, primarily due to reduced research funding from collaboration with Indivior [27] - R&D expenses were CHF2.8 million in Q3 2022, slightly down from CHF2.9 million in Q3 2021, attributed to reduced dipraglurant development activities [28] - G&A expenses increased to CHF1.8 million in Q3 2022 from CHF1.5 million in Q3 2021, mainly due to higher share-based compensation costs [28] - The company completed Q3 2022 with cash reserves of CHF10.4 million, providing a cash runway through Q2 2023 [5][29] Business Line Data and Key Metrics Changes - The GABAB PAM program is progressing towards late clinical candidate selection, with multiple candidates being profiled [4][17] - The mGluR7 negative allosteric modulator program has selected a clinical candidate ready to enter IND-enabling studies [22] - The mGluR2 NAM program is in the clinical candidate selection phase, with plans to start IND-enabling studies in the second half of 2023 [24] Market Data and Key Metrics Changes - The epilepsy market remains a significant opportunity, with the anti-epileptic market estimated at close to $20 billion in sales revenue [8] - The company’s partner, Janssen Pharmaceuticals, is on track to complete Part 1 of the Phase 2 epilepsy clinical study, with results expected in Q1 2023 [29] Company Strategy and Development Direction - The company aims to develop independent programs in Charcot-Marie-Tooth 1A neuropathy, chronic cough, and pain, alongside its partnered programs [4][18][20] - The focus on allosteric modulation is expected to yield differentiated drug candidates with improved efficacy and safety profiles compared to existing treatments [17][25] Management's Comments on Operating Environment and Future Outlook - Management expressed moderate confidence in closing a partnership deal by mid-next year, emphasizing the importance of securing a partner for restarting development activities [33] - The company recognizes its disappointing stock performance but believes successful execution of its partnering strategy will enhance stock value [30] Other Important Information - The company has retained rights to select drug candidates from the Indivior-funded research activities for its independent GABAB PAM program [4][17] - The company is pursuing multiple business discussions related to dipraglurant for various indications and plans to restart development once a partner is secured [14][29] Q&A Session Summary Question: Can you provide more details on your BD efforts and the timeline for closing a deal? - Management stated that discussions are ongoing with multiple potential partners for dipraglurant and expressed moderate confidence in closing a deal by mid-next year [33] Question: What is the main goal of Part 1 of the epilepsy study and what follows after? - The goal of Part 1 is to evaluate the difference in time to baseline seizure counts between the active group and placebo group, with results expected in Q1 2023 [35]

Addex Therapeutics Ltd (NASDAQ:ADXN) Q2 2022 Earnings Conference Call August 18, 2022 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and CEO Roger Mills - Chief Medical Officer Robert Lütjens - Head of Discovery, Biology Conference Call Participants Raghuram Selvaraju - HC Wainwright Bob Pooler - valuationLAB AG Operator Good day and thank you for standing by. Welcome to the Addex Therapeutics to Announce Half Year 2022 Financial Results and provide Corporate Update Conference Call. ...

Financial Data and Key Metrics Changes - In 2021, the company recognized $3.2 million in revenue, an increase from $2.9 million in 2020, primarily from research funding with Indivior [23] - R&D expenses rose to $12.8 million, up by $2.5 million compared to 2020, due to increased activities in the Dipraglurant and GABAB PAM programs [23] - G&A expenses were $5.8 million, slightly up from $5.7 million in 2020, attributed to higher insurance premiums [24] - The company ended the year with a cash position of CHF20.5 million, equivalent to $22.5 million [6][25] Business Line Data and Key Metrics Changes - The company has three clinical programs actively dosing patients, including Dipraglurant for blepharospasm and dyskinesia associated with Parkinson's Disease [3][26] - The pivotal Phase 2b/3 study for Dipraglurant in PD-LID began in Q2 2021, enrolling 140 patients [7] - The exploratory study for blepharospasm involves 15 patients and is expected to report data in Q2 2022 [12] Market Data and Key Metrics Changes - The market opportunity for Dipraglurant in dyskinesia associated with Parkinson's Disease is described as multi-billion dollars [7] - There are approximately 50,000 patients in the U.S. suffering from blepharospasm, with about 2,000 new cases annually [51] Company Strategy and Development Direction - The company aims to maintain the integrity and quality of its clinical studies despite delays caused by the pandemic [4] - A strategic collaboration with Indivior was extended, with an additional $4 million committed for research funding [5] - The company is focused on advancing multiple preclinical programs, including mGlu7 NAM for PTSD and mGlu2 NAM for mild neurocognitive disorders [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing clinical trials and the potential for significant data readouts in 2022 [27] - The company anticipates a promising outlook, highlighting the undervalued equity story and the potential for partnerships as clinical data emerges [27] Other Important Information - The company has made significant progress in its preclinical portfolio, with multiple drug candidates advancing towards IND-enabling studies [22] - The company is exploring non-dilutive funding opportunities for its PTSD program, which has garnered interest from governmental entities [43] Q&A Session Summary Question: Is enrollment for the PD-LID Dipraglurant study hastening as the Omicron wave recedes? - Management noted good momentum in enrollment as COVID impacts lessen, with encouraging activity across various sites [30] Question: What is the strategic positioning for Dipraglurant regarding different indications? - Management indicated that data from the blepharospasm study will inform future development strategies, with a focus on a strong signal from the exploratory study [35] Question: What is the timing for Indivior's decision on extending the collaboration? - The collaboration is currently under review, with discussions expected as the program reaches advanced stages of clinical candidate selection [42] Question: Can you provide guidance on cash burn and cash reach? - The company reported a cash burn of approximately CHF1.5 million per month, guiding cash availability into the first half of 2023 [46] Question: What is the market potential for the blepharospasm indication? - The company estimates around 50,000 patients in the U.S. with blepharospasm, highlighting the impactful nature of the condition [51] Question: When can we expect lead candidates in clinical trials for the GABAB PAM program? - The company anticipates moving candidates into IND-enabling studies by the end of 2022, with Phase 1 trials potentially starting in late 2023 [55] Question: Will positive results from the ADX71149 epilepsy study trigger a milestone payment? - Management clarified that the last milestone was received when the program entered Phase 2, and no further details on future milestones could be provided [58][59]

EXHIBIT 99.1 Addex Reports Full Year 2021 Financial Results and Provides Corporate Update CHF20.5M ($22.5M) of cash and cash equivalents at December 31, 2021 Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022 Phase 2b/3 dipraglurant study in dyskinesia associated with Parkinson's disease expected to report data in H1 2023 Janssen led ADX71149 Phase 2 study in epilepsy on track to report data in Q3 2022 Indivior GABAB PAM strategic collaboration extended with $4M additional ...